Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Medicure Inc. stock logo
MPH
Medicure
C$1.25
-1.6%
C$1.04
C$0.63
C$1.27
C$13.05M0.94,035 shs1,500 shs
Orphazyme A/S stock logo
ORPH
Orphazyme A/S
$1.43
$0.51
$77.77
$30.72M1.681.37 million shs941,400 shs
The 10 Best AI Stocks to Own in 2025 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Medicure Inc. stock logo
MPH
Medicure
0.00%0.00%+6.84%+83.82%+6.84%
Orphazyme A/S stock logo
ORPH
Orphazyme A/S
0.00%0.00%0.00%0.00%0.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Medicure Inc. stock logo
MPH
Medicure
N/AN/AN/AN/AN/AN/AN/AN/A
Orphazyme A/S stock logo
ORPH
Orphazyme A/S
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Medicure Inc. stock logo
MPH
Medicure
0.00
N/AN/AN/A
Orphazyme A/S stock logo
ORPH
Orphazyme A/S
0.00
N/AN/AN/A
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Medicure Inc. stock logo
MPH
Medicure
C$21.08M0.62C$0.50 per share2.49C$1.91 per share0.65
Orphazyme A/S stock logo
ORPH
Orphazyme A/S
N/AN/AN/AN/A$2.74 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Medicure Inc. stock logo
MPH
Medicure
-C$2.03M-C$0.19N/AN/A-9.65%-10.18%-5.63%N/A
Orphazyme A/S stock logo
ORPH
Orphazyme A/S
-$97.01MN/A0.00N/AN/AN/AN/AN/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Medicure Inc. stock logo
MPH
Medicure
N/A2.24%N/AN/AN/A
Orphazyme A/S stock logo
ORPH
Orphazyme A/S
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Medicure Inc. stock logo
MPH
Medicure
4.65
2.03
1.29
Orphazyme A/S stock logo
ORPH
Orphazyme A/S
0.14
1.80
N/A

Institutional Ownership

CompanyInstitutional Ownership
Medicure Inc. stock logo
MPH
Medicure
23.10%
Orphazyme A/S stock logo
ORPH
Orphazyme A/S
10.74%

Insider Ownership

CompanyInsider Ownership
Medicure Inc. stock logo
MPH
Medicure
26.68%
Orphazyme A/S stock logo
ORPH
Orphazyme A/S
N/A
CompanyEmployeesShares OutstandingFree FloatOptionable
Medicure Inc. stock logo
MPH
Medicure
N/A10.44 millionN/ANot Optionable
Orphazyme A/S stock logo
ORPH
Orphazyme A/S
14135.31 millionN/ANot Optionable

Recent News About These Companies

Artiphon’s new Orba instrument can sample sounds live

Media Sentiment Over Time

Medicure stock logo

Medicure CVE:MPH

C$1.25 -0.02 (-1.57%)
As of 06/27/2025

Medicure Inc., a biopharmaceutical company, engages in the research, development, and commercialization of human therapies in the United States. The company markets and distributes AGGRASTAT injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome, including unstable angina and non-Q-wave myocardial infarction. It also offers ZYPITAMAG to treat patients with primary hyperlipidemia or mixed dyslipidemia. In addition, the company is developing Sodium Nitroprusside injection, and Generic ANDA 2 and 3 for acute cardiology; and TARDOCAL, to treat neurological indications. It offers products through retail and mail order pharmacies. The company was incorporated in 1997 and is headquartered in Winnipeg, Canada.

Orphazyme A/S stock logo

Orphazyme A/S NASDAQ:ORPH

Orphazyme A/S, a biopharmaceutical company, develops therapies for the treatment of neurodegenerative orphan diseases. The company focuses on the amplification of heat-shock proteins to develop and commercialize therapeutics for diseases caused by protein misfolding and aggregation, and lysosomal dysfunction, including lysosomal storage and neuromuscular degenerative diseases. Its lead candidate is the Arimoclomol, which is in clinical development for four orphan diseases, including Niemann-Pick disease type C, Amyotrophic Lateral Sclerosis, Inclusion Body Myositis, and Gaucher disease. The company was incorporated in 2009 and is headquartered in Copenhagen, Denmark.